⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17177228 | 0.88 | — | — | |
| SCHEMBL23570096 | 0.88 | — | — | |
| SCHEMBL18133745 | 0.80 | — | — | |
| SCHEMBL14930347 | 0.80 | — | — | |
| SCHEMBL14985384 | 0.80 | — | — | |
| SCHEMBL21910033 | 0.78 | — | — | |
| SCHEMBL21567214 | 0.76 | — | — | |
| SCHEMBL15038033 | 0.76 | — | — | |
| SCHEMBL18270978 | 0.76 | — | — | |
| SCHEMBL25700477 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024039858-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | OLEMA PHARMACEUTICALS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| EP-4169913-A1 | SUBSTITUTED PYRAZINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2023-04-26 | — | — | EP | disclosed |
| US-20220033376-A1 | ESTROGEN RECEPTOR ANTAGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-02-03 | — | — | US | disclosed |
| WO-2021259077-A1 | SUBSTITUTED PYRAZINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2021-12-30 | — | — | WO | disclosed |
| EP-3889133-A1 | ESTROGEN RECEPTOR ANTAGONIST | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| EP-3303326-B1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2020-12-16 | — | — | EP | disclosed |
| WO-2020125640-A1 | ESTROGEN RECEPTOR ANTAGONIST | 正大天晴药业集团股份有限公司 | 2020-06-25 | — | — | WO | disclosed |
| EP-2791133-B1 | FLUORINATED ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS INC (US) | 2019-04-17 | — | — | EP | disclosed |
| US-10227334-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170275273-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20160175284-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-23 | — | — | US | disclosed |
| US-9249158-B2 | Cytomegalovirus inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-02 | — | — | US | disclosed |
| US-9193714-B2 | Fluorinated estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150258080-A1 | THERAPEUTIC COMBINATIONS WITH ESTROGEN RECEPTOR MODULATORS | GENENTECH, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150258099-A1 | METHODS AND COMPOSITIONS FOR MODULATING ESTROGEN RECEPTOR MUTANTS | GENENTECH, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150080366-A1 | CYTOMEGALOVIRUS INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-03-19 | — | — | US | disclosed |
| US-20150005286-A1 | FLUORINATED ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. | 2015-01-01 | — | — | US | disclosed |
| WO-2013152065-A2 | CYTOMEGALOVIRUS INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013090836-A1 | FLUORINATED ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |